Effect of transdermal @entity172 therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal XXXX .

@entity172 @entity1 @entity7 @entity1421 @entity53 @entity4770 @entity842 @entity916 @entity551
BACKGROUND: Mechanisms of the vasoprotective effect of hormone replacement therapy (HRT) are not completely understood, and they may involve direct actions on blood vessels through modulation of endogenous vasoconstrictors and vasodilators. Most studies have focused on @entity172 action on @entity4770 and @entity842 , while insufficient data exist concerning the effect of @entity172 replacement therapy (ERT) on @entity7 ( @entity7 ) and @entity1421 . OBJECTIVE: The aim of this study was to examine the effect of transdermal @entity172 therapy on @entity7 , @entity1421 and active @entity916 in normotensive postmenopausal @entity1 . METHODS: Transdermal @entity172 (Climara) (Schering): 50 microg @entity53 ) was given for 3 months to normotensive @entity1 with a surgically induced menopause, and serum levels of @entity7 , active @entity916 and @entity1421 were measured before and after treatment. In addition, 24-h ambulatory blood pressure monitoring was carried out to determine the @entity172 action on mean diurnal and nocturnal systolic and diastolic blood pressure levels. RESULTS: @entity53 treatment resulted in a significant increase in both @entity7 and @entity1421 . There was no significant change in active @entity916 levels. However, out- @entity1 monitoring showed a significant @entity551 (daytime, night-time and total 24-h). The stimulating action of ERT on @entity7 and @entity1421 suggests that both factors can elicit @entity172 vasodilatory effects. CONCLUSION: The @entity172 -mediated increase in serum @entity7 and @entity1421 concentrations may be a mechanism by which HRT benefits the cardiovascular system.
